Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 2387-08-8 | MDL No. : | MFCD11855825 |
Formula : | C7H7Cl2N | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | QFUZJHWRUZVIOF-UHFFFAOYSA-N |
M.W : | 176.04 | Pubchem ID : | 343796 |
Synonyms : |
|
Num. heavy atoms : | 10 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.14 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 0.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 45.83 |
TPSA : | 26.02 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.07 cm/s |
Log Po/w (iLOGP) : | 1.95 |
Log Po/w (XLOGP3) : | 3.25 |
Log Po/w (WLOGP) : | 2.89 |
Log Po/w (MLOGP) : | 2.99 |
Log Po/w (SILICOS-IT) : | 2.85 |
Consensus Log Po/w : | 2.79 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 2.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -3.42 |
Solubility : | 0.0665 mg/ml ; 0.000378 mol/l |
Class : | Soluble |
Log S (Ali) : | -3.47 |
Solubility : | 0.0596 mg/ml ; 0.000339 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -3.65 |
Solubility : | 0.039 mg/ml ; 0.000222 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.16 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
84% | Stage #1: With acetic anhydride In chloroform at 0 - 20℃; Stage #2: With potassium acetate; isopentyl nitrite In chloroformReflux |
Step 25 ,6-Dichloro-l H-indazolTo a solution of 4,5-dichloro-2-methylaniline (1.69 g, 9.6 mmol) in CHC13 (25 ml) at 0°C was slowly added acetic anhydride (2.09 ml, 22.1 mmol). The reaction mixture was warmed to room temperature and stirred for 1 h. A thick white precipitate had gradually formed. Potassium acetate (283 mg, 2.88 mmol) was added followed by slow addition of isoamyl nitrite (2.78 ml, 20.6 mmol). The reaction mixture was heated at reflux overnight. The homogeneous deep orange reaction mixture was cooled to room temperature and concentrated. Water (10 mL) was added and the mixture was reconcentrated to an orange solid. This solid was suspended in cone. HCl (15 mL) and heated at 60°C for 2 h then cooled to 0°C and neutralized with 50percent NaOH. Extracted with EtOAc, dried over MgS04 and concentrated to an orange solid. This solid was dissolved in THF/MeOH (1 :1 , 25 mL) and 10percent> NaOH (3 mL) was added. The deep maroon reaction mixture was stirred at room temperature for 5 min then neutralized with 1.0 M HCl and diluted with water. The mixture was extracted with EtOAc (2 x) then dried over MgS04 and concentrated. The residue was absorbed onto silica gel and purified by chromatography with 30percent to 50percent EtOAc/hexanes to afford 1.50 g (84percent) of 5, 6-dichloro-l H-indazole as a light orange solid. 1H NMR (CDC13, 300 MHz): ? (ppm) 8.04 (s, 1H), 7.89 (s, 1H), 7.68 (s, 1H). |
[ 5769-32-4 ]
4-Chloro-2,6-dimethylaniline hydrochloride
Similarity: 0.93
[ 5769-32-4 ]
4-Chloro-2,6-dimethylaniline hydrochloride
Similarity: 0.93
[ 5769-32-4 ]
4-Chloro-2,6-dimethylaniline hydrochloride
Similarity: 0.93